Amgen Says FDA Completes Review Of SNDA Seeking Full Approval For LUMAKRAS

RTTNews | 485 ngày trước
Amgen Says FDA Completes Review Of SNDA Seeking Full Approval For LUMAKRAS

(RTTNews) - Amgen, Inc. (AMGN) announced Tuesday that the U.S. Food and Drug Administration (FDA) has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS (sotorasib).

The review, which resulted in a Complete Response Letter, was based on the CodeBreaK 200 trial results for the treatment of adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC).

The FDA also issued a new postmarketing requirement (PMR) for an additional confirmatory study to support full approval that will be completed no later than February 2028.

In addition, the FDA concluded that the dose comparison PMR issued at the time of LUMAKRAS accelerated approval, to compare the safety and efficacy of LUMAKRAS 960 mg daily dose versus a lower daily dose, has been fulfilled.

The company said LUMAKRAS at 960 mg once-daily will remain the dose for patients with KRAS G12C-mutated NSCLC under accelerated approval.

read more
Amgen's Bkemv Approved As First Interchangeable Biosimilar To Soliris

Amgen's Bkemv Approved As First Interchangeable Biosimilar To Soliris

The U.S. Food and Drug Administration has approved Amgen Inc.'s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab), developed by British drug major AstraZeneca's Rare Disease unit Alexion Pharmaceuticals, to treat certain rare diseases. Soliris is a medicine used to treat adults and children with paroxysmal nocturnal haemoglobinuria or PNH...
RTTNews | 330 ngày trước
Amgen Announces Positive Top-line Results From Phase 3 DAHLIA Study Of ABP 959

Amgen Announces Positive Top-line Results From Phase 3 DAHLIA Study Of ABP 959

Amgen, Inc. (AMGN) announced Tuesday positive top-line results from the DAHLIA study, a randomized, double-blind, active-controlled, two-period crossover Phase 3 study evaluating the efficacy and safety of ABP 959, a biosimilar candidate to SOLIRIS (eculizumab), compared with SOLIRIS in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
RTTNews | 975 ngày trước
Sensex, Nifty Edge Higher In Cautious Trade

Sensex, Nifty Edge Higher In Cautious Trade

Indian shares traded slightly higher on Friday, mirroring firm cues from global markets as traders hoped for favorable outcome from ongoing trade negotiations and comments by a Federal Reserve official bolstered odds that the central bank will cut interest rates as early as June.
RTTNews | 1h 25phút trước
Asian Markets Track Wall Street Higher

Asian Markets Track Wall Street Higher

Asian stock markets are mostly higher on Friday, following the broadly positive from Wall Street overnight, as traders remain optimistic about a favorable outcome from the ongoing tariff negotiations between the U.S. and several partner countries, particularly China, Japan, South Korea and India. Comments from two US Fed officials about cutting interest rates also improved market sentiment.
RTTNews | 2h 22phút trước
Japanese Market Sharply Higher

Japanese Market Sharply Higher

Extending the gains in the previous two sessions, the Japanese market is sharply higher on Friday, following the broadly positive cues from Wall Street overnight. The Nikkei 225 is surging to stay just below the 35,600 level, with gains across all sectors led by index heavyweights, exporters and technology stocks.
RTTNews | 2h 48phút trước
Sensex, Nifty Seen Higher At Open

Sensex, Nifty Seen Higher At Open

Indian shares look set to open higher on Friday after U.S. Treasury Secretary Scott Bessent said the U.S. and South Korea could reach an "agreement of understanding" on trade as soon as next week.
RTTNews | 3h 2phút trước